Search

A study published in the journal Nephrology Dialysis Transplantation examined the effectiveness of obinutuzumab in treating frequently-relapsing/steroid-dependent minimal change disease (MCD) in adults. The study found that obinutuzumab, a type II anti-CD20 monoclonal antibody, was effective in achieving remission in patients with FR/SD MCD. The study included six patients, and the treatment involved a combination of glucocorticosteroids and obinutuzumab. Further research is needed to determine the long-term efficacy and safety of obinutuzumab for MCD. The article also discusses the use of obinutuzumab in the treatment of focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD) in adult patients. The study included six patients with FSGS or MCD who were treated with obinutuzumab. After treatment, all six patients achieved complete remission, and there were no relapses during the follow-up period. The study suggests that obinutuzumab may be an effective and safe treatment option for adult patients with FSGS or MCD. However, the study has limitations, including a small sample size and short follow-up time, and further research is needed to fully understand the long-term outcomes and mechanisms of obinutuzumab treatment. [Extracted from the article]

B-cell novel protein 1 (BCNP1) has recently been identified as a new B-cell receptor (BCR) signaling molecule but its physiological function remains unknown. Here, we demonstrate that mice deficient in BCNP1 exhibit impaired B-cell maturation and a reduction of B-1a cells. BCNP1-deficient spleen B cells show enhanced survival, proliferation and Ca2+ influx in response to BCR cross-linking as compared with wild-type spleen B cells. Consistently, mutant B cells show elevated phosphorylation of SYK, B-cell linker protein (BLNK) and PLCγ2 upon BCR cross-linking. In vivo , BCNP1-deficient mice exhibit enhanced humoral immune responses to T-independent and T-dependent antigens. Moreover, aged mutant mice contain elevated levels of serum IgM and IgG3 antibodies and exhibit polyclonal and monoclonal B-cell expansion in lymphoid organs. These results reveal distinct roles for BCNP1 in B-cell development, activation and homeostasis. [ABSTRACT FROM AUTHOR]

The B‐cell receptor (BCR) transmits a tonic survival signal in the absence of antigen stimulation and an antigen‐triggered survival signal. Mature B cells express two types of BCR, IgM and IgD, but it remains unclear how B‐cell survival is differentially regulated by these two receptors. We found that, whereas cross‐linking IgM on spleen B cells greatly enhanced their survival, cross‐linking IgD did not enhance, but rather decreased, their survival. Consistently, cross‐linking both IgM and IgD only moderately enhanced B‐cell survival, suggesting that IgM and IgD play opposing roles in B‐cell survival induced by BCR stimulation. Based on these and additional experimental results, we present a mathematical model integrating IgM‐ and IgD‐mediated survival signals. Our model shows that IgD can transmit a tonic survival signal in the absence of antigen stimulation but cross‐linking IgD not only does not generate a survival signal but also disrupts its tonic signal, resulting in inhibition of B‐cell survival. These results suggest that IgD attenuates BCR‐induced survival in mature B cells, presumably to restrain B‐cell response to weak and/or self‐antigens and prevent nonspecific B‐cell activation and autoimmunity. Cross‐linking IgM on B cells enhances B‐cell survival. In contrast, cross‐linking IgD inhibits B‐cell survival. Based on these and additional experimental results, the authors establish a mathematical model for BCR‐induced B‐cell survival. [ABSTRACT FROM AUTHOR]